Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742736 · ClinicalTrials.gov registry record
EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 13,000
- Enrollment target
NCT06742736: Completed study, sponsored by AstraZeneca.
NCT06742736 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 13,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06742736 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 13,000 participants
- Enrollment target
Study Summary
A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in the United States
Primary Outcome
Annualized rates of COPD exacerbation events observed from index date (qualifying exacerbation event) through study completion (or until end of data availability; mean follow-up 462 days
Interventions
- DRUG BGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,000 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2024-09-30 |
What the finished NCT06742736 record still lists
NCT06742736 is an observational study that tracks outcomes without assigning an intervention. Its 13,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which BGF is the first listed.
NCT06742736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06742736 about?
NCT06742736 is a clinical study titled "EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)". A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in the United States
What is the current status of trial NCT06742736?
This trial is currently completed. The enrollment target is 13,000 participants. The study started on 2024-05-31. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT06742736?
The interventions under investigation include: BGF (DRUG).
Who is sponsoring clinical trial NCT06742736?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
- NCT07177352 · 13,000 participants · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- NCT07028398 · 12,990 participants · NA
CMSL Ambulatory Sensitive Condition Nudge Study 2
- NCT03586895 · 12,838 participants · NA
e-Connect: A Service System Intervention for Justice Youth at Risk for Suicide
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI